Piyasa kapalı· · HKD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.
Non-small cell lung cancer is increasingly evolving into a biomarker-driven market, with EGFR-mutated disease emerging as one of the most commercially significant segments. The space is dominated by blockbuster EGFR-targeted therapies such as TAGRISSO, which now generates nearly USD 6 billion annually, reinforcing the importance of precision medicine in NSCLC management.
CSPC Pharmaceutical Group (SEHK:1093) has received regulatory approval in China to start clinical trials for its new antibody drug conjugate SYS6051. The therapy targets advanced solid tumors and has been cleared as a Class 1 biological drug candidate. The approval allows the company to begin clinical evaluation of SYS6051 across a broad range of advanced cancers. CSPC Pharmaceutical Group, a major player in China's pharmaceutical sector, has been building out its oncology pipeline...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.